– Patient-reported outcomes from Phase 2 trial of oxylanthanum carbonate (OLC) demonstrate high patient satisfaction with OLC compared to their prior phosphate lowering therapy – – Findings from a ...
WALTHAM, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines ...
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Once hyperphosphatemia occurs, we like to ...
(MENAFN- EIN Presswire) EINPresswire/ -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors What Is The Projected ...
Please provide your email address to receive an email when new articles are posted on . “So, what can we do beyond binders?” he asked during the presentation. One method is to increase the frequency ...
Tenapanor, a novel agent that has been submitted to the US Food and Drug Administration (FDA) for approval for the treatment of hyperphosphatemia in patients undergoing dialysis, moved a step closer ...
The FINANCIAL — Astellas Pharma Inc. announced that it launched Kiklin Granules 86.2% (generic name: bixalomer, “Kiklin Granules”), an additional formulation of Kiklin Capsules 250 mg (“Kiklin ...
Unicycive Therapeutics, Inc. UNCY, a clinical-stage company, issued a letter to its shareholders providing corporate updates and key upcoming milestones for the company in 2024. Following the issuance ...
WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results